PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada

Trial Profile

PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms PEGASUS
  • Sponsors Bayer
  • Most Recent Events

    • 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2016 Planned End Date changed from 1 May 2018 to 1 Dec 2017.
    • 14 Nov 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top